Quantum BioPharma Ltd. Advances Diversified Platform Targeting Neurodegenerative and Metabolic Disorders

Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) is a biopharmaceutical company focused on developing therapies and biotech solutions targeting neurodegenerative, metabolic and alcohol misuse disorders, according to a recent article highlighting the company's diversified platform. The company's strategy combines pharmaceutical research and development with commercialization partnerships and licensing structures intended to support multiple potential revenue streams and long-term growth initiatives. Quantum BioPharma is advancing programs across multiple stages of development while leveraging scientific research, intellectual property and commercial relationships as part of its broader business strategy.

Through its wholly owned subsidiary, Lucid Psycheceuticals Inc. (Lucid), Quantum is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. This compound represents a potential breakthrough in the treatment of multiple sclerosis, a chronic neurodegenerative disease affecting millions worldwide.

In addition to its pharmaceutical pipeline, Quantum has developed UNBUZZD, a consumer-focused product aimed at alcohol misuse. The company spun out its OTC version to Unbuzzd Wellness Inc. (formerly Celly Nutrition Corp.), led by industry veterans. Quantum retains ownership of 19.84% (as of March 31, 2026) of Unbuzzd at unbuzzd.com. The agreement with Unbuzzd also includes royalty payments of 7% of sales from unbuzzd until payments to Quantum total $250 million. Once $250 million is reached, the royalty drops to 3% in perpetuity. Quantum retains 100% of the rights to develop similar products or alternative formulations specifically for pharmaceutical and medical uses.

The company's approach of combining clinical-stage therapeutics with consumer health products and strategic investments creates a diversified revenue model that could mitigate risk and accelerate growth. By addressing areas of significant unmet need, such as multiple sclerosis and alcohol misuse, Quantum BioPharma positions itself at the intersection of innovation and market demand. Investors can find the latest news and updates relating to QNTM in the company’s newsroom at https://ibn.fm/QNTM.